Researchers escalated concerns after finding evidence of altered antibody validation images in vendor catalog data, sparking broader backlash against Thermo Fisher Scientific’s online antibody listings. An initial discovery by UK molecular biologist Sholto David and analysis by Reese Richardson at Northwestern University led to a growing repository documenting image-manipulation patterns, including cropping/pasting and band repositioning. The dispute centered on whether changes were merely presentation adjustments or indicate deeper fabrication concerns. Thermo Fisher maintains it did not manipulate or fabricate data beyond modifying images for website display, but researchers said they remain uneasy about ordering and trust in the validation process. For the biotech ecosystem, the controversy raises procurement and reproducibility risk, potentially forcing labs to add more internal verification steps or reconsider vendor validation practices for critical reagents.